As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.
On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work
outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.
The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.
Shijiazhuang Yiling Pharmaceutical primarily manufactures Western drugs, but also has a focus on traditional Chinese medicine. The company’s product portfolio includes cardiovascular, influenza antiviral, diabetes, and anticancer drugs. It exports to South Korea, Canada, Singapore, Russia, Vietnam, and Indonesia. One of its influenza antiviral drugs is currently under clinical trials and is seeking US Food and Drug Administration approval.
Yiling Pharmaceutical Inc. 5348 Vegas Drive, Las Vegas, NV 89108
The company invested $15 million in HealthWatch Ltd., a wearable medical device company based in Israel. Meanwhile, the company, HealthWatch, and another Chinese investment firm plan to form a joint venture that specializes in electrocardiogram monitors in China.